调强放疗联合替吉奥治疗食管癌的临床效果

Clinical efficacy evaluation of intensity modulated radiotherapy combined with tegafur gimeracil oteracil potassium capsule in the treatment of esophageal cancer

目的探讨调强放疗联合替吉奥治疗食管癌的价值。方法选取2018年1月至2021年10月南通瑞慈医院诊治的食管癌患者124例,按照随机数表法分为对照组及观察组,每组各62例,分别应用单纯替吉奥治疗及调强放疗联合替吉奥治疗,观察指标包括肿瘤标志物、治疗效果及安全性。结果治疗前两组CA125、CEA、CA199比较,差异无统计学意义(P>0.05)。治疗后观察组CA125为(33.45±8.22)U/ml、CEA为(2.16±0.76)ng/L、CA199为(31.22±4.62)U/ml,低于对照组的(44.67±9.04)U/ml、(3.89±0.98)ng/L、(38.65±5.67)U/ml,差异有统计学意义(P<0.05);观察组有效率为82.26%、疾病控制率为93.55%,高于对照组的61.29%、80.65%,差异有统计学意义(P<0.05)。两组毒副反应总发生率比较,差异无统计学意义(P>0.05)。结论对食管癌患者应用替吉奥的同时进行调强放疗,可有效提高治疗效果,且不增加毒副反应,值得推广。

Objective To explore the value of intensity modulated radiotherapy combined with tegafur gimeracil oteracil potassium capsule in the treatment of esophageal cancer.Methods A total of 124 patients with esophageal cancer admitted to Nantong Rich Hospital from January 2018 to October 2021 were selected,and they were divided into the control group and the observation group by random number table method,with 62 cases in each group.The patients were treated with tegafur gimeracil oteracil potassium capsule and intensity modulated radiotherapy combined with tegafur gimeracil oteracil potassium capsule respectively,with the observation indicators of tumor markers,therapeutic efficacy and safety.Results There were no statistically significant differences in CA125,CEA and CA199 between the two groups before treatment(P>0.05),but CA125(33.45±8.22)U/ml,CEA(2.16±0.76)ng/L and CA199(31.22±4.62)U/ml of the observation group were significantly lower than those(CA125[44.67±9.04]U/ml,CEA[3.89±0.98]ng/L,CEA[38.65±5.67]U/ml)of the control group after treatment(P<0.05).The effective rate(82.26%)and disease control rate(93.55%)of the observation group were significantly higher than those(61.29%and 80.65%)of the control group(P<0.05).There were no statistically significant differences in total incidence of toxic and side effects between the two groups(P>0.05).Conclusion The application of tegafur gimeracil oteracil potassium capsule combined with intensity modulated radiotherapy in patients with esophageal cancer can effectively improve the therapeutic efficacy without increasing toxic and side effects,which is worthy of promotion.